Viewpoint Molecular Targeting, Inc.: Viewpoint Molecular Targeting Enters into Long-Term Supply Agreement with the National Isotope Development Center of the U.S. Department of Energy Isotope Program
??
-GEN isotope generator, which enables a nimble supply of therapeutic radioisotopes with the power of alpha-particle therapy for cancer
CORALVILLE, IA / ACCESSWIRE / February 18, 2021
/ Viewpoint Molecular Targeting, Inc. ("Viewpoint" or the "Company"), a radiopharmaceutical company developing precision α-particle oncology
therapeutics and complementary diagnostic imaging agents, today announced it has entered into an agreement with the National Isotope Development Center (NIDC) for the long-term supply of parent feedstock radionuclide Th-228 for the manufacturing of the Company's Ra-224/Pb-212 generator, VMT-??-GEN. The long-term agreement provides deliveries from 2021 through 2030.